Aspira women's health reports fourth quarter and full year 2024 financial results

Record 2024 ovasuite revenue of $9.2 million and volume of 24,305 units sold austin, tx / access newswire / march 27, 2025 / aspira women's health inc. ("aspira" or the "company") (nasdaq:awh), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended december 31, 2024. select financial results are as follows: fourth quarter 2024 and recent financial highlights • product revenue increased 9.5% to $2.3 million for the three months ended december 31, 2024, compared to $2.1 million for the same period in 2023.
AWH Ratings Summary
AWH Quant Ranking